914453-96-6

914453-96-6 structure

Name: Terlipressin Acetate
Chemical Name: Terlipressin Acetate
CAS Number: 914453-96-6
Molecular Formula: C₅₂H₇₄N₁₆O₁₅S_2.xC₂H₄O₂
Molecular Weight: 1347.476
Catalog: Signaling Pathways GPCR/G Protein Vasopressin Receptor
Create Date: 2018-03-19 08:00:00
Modify Date: 2024-01-08 16:41:04
Terlipressin acetate is a vasopressin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controlling acute variceal bleeding. Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock treatment[1][2][3][4][5].

Name	Terlipressin Acetate
Synonyms	(2S)-1-{[(4R,7S,10S,13S,16S,19R)-19-{[({[(Aminoacetyl)amino]acetyl}amino)acetyl]amino}-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-N-{(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxo-2-hexanyl}-2-pyrrolidinecarboxamide acetate (1:2)

Description	Terlipressin acetate is a vasopressin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controlling acute variceal bleeding. Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock treatment[1][2][3][4][5].
Related Catalog	Research Areas >> Cardiovascular Disease Research Areas >> Endocrinology Signaling Pathways >> GPCR/G Protein >> Vasopressin Receptor Research Areas >> Inflammation/Immunology
Target	Vasopressin V1 receptor[1]
In Vitro	Terlipressin (25 nM; 24-72 hours; IEC-6 cells) treatment significantly improves cell viability, proliferation and apoptosis in IEC-6 cells[1]. Terlipressin inhibits the secretion of TNF-α and 15-F2t-isoprostane from IEC-6 cells following oxygen and glucose deprivation/re-oxygenation (OGD/R). Terlipressin administration following OGD attenuates OGD/R-induced cell damage via the PI3K signaling pathway[1]. Cell Proliferation Assay[1] Cell Line: IEC-6 cells induced by oxygen and glucose deprivation/re-oxygenation (OGD/R) Concentration: 25 nM Incubation Time: 24 hours, 48 hours, 72 hours Result: Significantly increased the proliferation of IEC-6 cells.
In Vivo	Using a mouse nonlethal hepatic ischemia-reperfusion (IR) model, Terlipressin administration significantly ameliorates IR-induced liver apoptosis, necrosis and inflammation[3].
References	[1]. Zi-Meng Liu, et al. Terlipressin Protects Intestinal Epithelial Cells Against Oxygen-Glucose Deprivation/Re-Oxygenation Injury via the Phosphatidylinositol 3-kinase Pathway. Exp Ther Med. 2017 Jul;14(1):260-266. [2]. Yeun Tarl Fresner Ng Jao, et al. Refractory Torsade De Pointes Induced by Terlipressin (Glypressin). Int J Cardiol. 2016 Nov 1;222:135-140. [3]. Xiqiang Liu, et al. Signaling Through Hepatocyte Vasopressin Receptor 1 Protects Mouse Liver From Ischemia-Reperfusion Injury. Oncotarget. 2016 Oct 25;7(43):69276-69290. [4]. Xinmiao Zhou, et al. Terlipressin for the Treatment of Acute Variceal Bleeding: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore). 2018 Nov;97(48):e13437. [5]. Alastair O'Brien, et al. Terlipressin for Norepinephrine-Resistant Septic Shock. Lancet. 2002 Apr 6;359(9313):1209-10.

Molecular Formula	C₅₂H₇₄N₁₆O₁₅S_2.xC₂H₄O₂
Molecular Weight	1347.476
Exact Mass	1346.538330
Storage condition	-20°C

914453-96-6	1884420-36-3
14636-12-5	54324-99-1
6426-44-4	29066-34-0
5205-07-2	10483-91-7
6046-93-1	27569-23-9
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	2229574-06-3
2172328-42-4	930439-75-1
1018584-77-4	1375289-11-4